Medicure Inc. (TSXV:MPH)

Market Cap	12.84M -20.6%
Revenue (ttm)	26.21M +24.3%
Net Income	-3.43M
EPS	-0.33
Shares Out	10.44M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	2,142
Open	1.220
Previous Close	1.120
Day's Range	1.220 - 1.230
52-Week Range	0.630 - 1.430
Beta	0.96
RSI	53.87
Earnings Date	Apr 28, 2026

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 38
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MPH

Financial Performance

In 2024, Medicure's revenue was 21.91 million, an increase of 0.98% compared to the previous year's 21.69 million. Losses were -1.04 million, 12.7% more than in 2023.